Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 2/23/2026 | $1280.00 | Neutral → Buy | UBS | |
| 2/20/2026 | $155.00 | Equal Weight | Barclays | |
| 2/11/2026 | $140.00 → $170.00 | Buy | Needham | |
| 1/14/2026 | $1209.00 | Buy → Hold | TD Cowen | |
| 1/7/2026 | $145.00 | Buy | UBS | |
| 12/17/2025 | $32.00 | Buy → Hold | Jefferies | |
| 12/15/2025 | $32.00 | Buy → Hold | Deutsche Bank | |
| 12/11/2025 | $1180.00 | Neutral | UBS |
Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-6) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215973, Application Classification: Efficacy
Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-8) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215974, Application Classification: Efficacy
Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-9) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/13/2024. Application Category: NDA, Application Number: 215973, Application Classification: Manufacturing (CMC)
10-K - BlackRock, Inc. (0002012383) (Filer)
IRANNOTICE - BlackRock, Inc. (0002012383) (Filer)
144 - BlackRock, Inc. (0002012383) (Subject)
UBS upgraded BlackRock from Neutral to Buy and set a new price target of $1,280.00
Barclays initiated coverage of Gilead Sciences with a rating of Equal Weight and set a new price target of $155.00
Needham reiterated coverage of Gilead Sciences with a rating of Buy and set a new price target of $170.00 from $140.00 previously
Delivers 2025 Results Consistent with GuidancePerformance Led by Strong Momentum in U.S. Refreshment BeveragesTargets Double-Digit Adjusted EPS Growth in 2026, Including Anticipated JDE Peet's ContributionRole of Board Chair to Transition from Bob Gamgort to Pamela Patsley BURLINGTON, Mass. and FRISCO, Texas, Feb. 24, 2026 /PRNewswire/ -- Keurig Dr Pepper Inc. (NASDAQ:KDP) today reported results for the fourth quarter and full year ended December 31, 2025 and provided guidance for 2026.Reported GAAP BasisAdjusted Basis1Q4FY 2025Q4FY 2025Net Sales$4.50 bn$16.60 bn$4.50 bn$16.60 bn% vs prior year10.5 %8.2 %9.9 %8.6 %Diluted EPS$0.26$1.53$0.60$2.05% vs prior year336.4 %45.7 %1.7 %7.3 %_________
TORONTO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- BlackRock Asset Management Canada Limited ("BlackRock Canada"), an indirect, wholly-owned subsidiary of BlackRock, Inc. (NYSE:BLK), today announced the final February 2026 cash distributions for the iShares Premium Money Market ETF. Unitholders of record on February 24, 2026 will receive cash distributions payable on February 27, 2026. Details regarding the final "per unit" distribution amounts are as follows: Fund NameFund Ticker Cash Distribution Per Unit iShares Premium Money Market ETFCMR$0.088 Further information on the iShares ETFs can be found at http://www.blackrock.com/ca. About BlackRockBlackRock's purpose is to help more and more peop
Company strengthens balance sheet by further reducing projected leverage and attracts additional high-quality investorsBURLINGTON, Mass. and FRISCO, Texas, Feb. 23, 2026 /PRNewswire/ -- Keurig Dr Pepper Inc. (NASDAQ:KDP, ", the Company", )) today announced updated financing plans and transaction timelines for the acquisition of JDE Peet's and subsequent planned separation into two independent companies ("Beverage Co." and "Global Coffee Co." pending the announcement of official corporate names).Key developments include:A targeted close of the JDE Peet's acquisition in early April 2026, with expected combined net leverage of approximately 4.5x1An agreement to upsize the previously announced B
4 - BlackRock, Inc. (0002012383) (Issuer)
4 - BlackRock, Inc. (0002012383) (Issuer)
4 - BlackRock, Inc. (0002012383) (Issuer)
4 - Keurig Dr Pepper Inc. (0001418135) (Issuer)
4 - Keurig Dr Pepper Inc. (0001418135) (Issuer)
4 - BlackRock, Inc. (0002012383) (Reporting)
Appoints two highly qualified independent directors to the Board Establishes new Board committees reinforcing strong governance BURLINGTON, Mass. and FRISCO, Texas, Feb. 12, 2026 /PRNewswire/ -- Keurig Dr Pepper (NASDAQ:KDP) today announced the continued evolution of its Board of Directors. Effective March 2, two new independent directors, Amie Thuener and William "Bill" Newlands, will join the Board. On the same date, the existing Remuneration & Nominating Committee will separate into newly-created Nominating & Governance and Compensation Committees. These changes support KDP's transformation and value creation agenda as it approaches the closing of the JDE Peet's acquisition in early Q2 a
Gilead Sciences, Inc. (NASDAQ:GILD) announced today that Keeley Wettan will be appointed Executive Vice President, General Counsel, Legal & Compliance effective immediately. She will join the company's senior leadership team and report to Chairman and Chief Executive Officer Daniel O'Day. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218926462/en/Gilead Sciences appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance Ms. Wettan has held increasingly senior legal leadership roles within Gilead during her 14-year tenure, most recently as Senior Vice President leading the Global Legal Business Par
Three College Students Each Awarded $100,000 in Tuition Funds FRISCO, Texas, Dec. 8, 2025 /PRNewswire/ -- Dr Pepper®, part of the Keurig Dr Pepper (NASDAQ:KDP) portfolio of brands, has announced the winners of the 18th annual Dr Pepper Tuition Giveaway, awarding three students each $100,000 in tuition funds during the three College Football Conference Championship games (SEC, Big Ten, ACC) on Saturday, December 6th. Six finalists participated in the Dr Pepper Tuition Giveaway where they competed against a peer to see who could throw the most footballs into an oversized Dr Pepper can in 30 seconds.
Delivers 2025 Results Consistent with GuidancePerformance Led by Strong Momentum in U.S. Refreshment BeveragesTargets Double-Digit Adjusted EPS Growth in 2026, Including Anticipated JDE Peet's ContributionRole of Board Chair to Transition from Bob Gamgort to Pamela Patsley BURLINGTON, Mass. and FRISCO, Texas, Feb. 24, 2026 /PRNewswire/ -- Keurig Dr Pepper Inc. (NASDAQ:KDP) today reported results for the fourth quarter and full year ended December 31, 2025 and provided guidance for 2026.Reported GAAP BasisAdjusted Basis1Q4FY 2025Q4FY 2025Net Sales$4.50 bn$16.60 bn$4.50 bn$16.60 bn% vs prior year10.5 %8.2 %9.9 %8.6 %Diluted EPS$0.26$1.53$0.60$2.05% vs prior year336.4 %45.7 %1.7 %7.3 %_________
Company strengthens balance sheet by further reducing projected leverage and attracts additional high-quality investorsBURLINGTON, Mass. and FRISCO, Texas, Feb. 23, 2026 /PRNewswire/ -- Keurig Dr Pepper Inc. (NASDAQ:KDP, ", the Company", )) today announced updated financing plans and transaction timelines for the acquisition of JDE Peet's and subsequent planned separation into two independent companies ("Beverage Co." and "Global Coffee Co." pending the announcement of official corporate names).Key developments include:A targeted close of the JDE Peet's acquisition in early April 2026, with expected combined net leverage of approximately 4.5x1An agreement to upsize the previously announced B
– Pivotal Phase 3 Findings Support the Potential of a Novel Single-Tablet Combination of Bictegravir and Lenacapavir for HIV Treatment – – Latest Data from the PURPOSE Program Further Demonstrates the Safety and Efficacy Profile of Twice-Yearly Lenacapavir for HIV Prevention – Gilead Sciences, Inc. (NASDAQ:GILD) today announced details of new clinical and real-world data from its innovative HIV treatment and prevention portfolio and research pipeline that will be presented at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI 2026) being held from February 22-25 in Denver, Colorado. Focusing on expanding therapeutic options to meet the diverse needs of communities af
SC 13G/A - BlackRock, Inc. (0002012383) (Filed by)
SC 13G - BlackRock, Inc. (0002012383) (Filed by)
SC 13G/A - BlackRock, Inc. (0002012383) (Filed by)